Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.
Antineoplastic Agents, Immunological
/ pharmacology
Biomarkers, Tumor
Carcinoma, Squamous Cell
/ drug therapy
Clinical Trials as Topic
Disease Management
Disease Susceptibility
ErbB Receptors
/ antagonists & inhibitors
Humans
Immune Checkpoint Proteins
/ genetics
Immunotherapy
Molecular Targeted Therapy
Prognosis
Skin Neoplasms
/ drug therapy
Treatment Outcome
Epidermal growth factor receptor (EGFR)
Programmed death ligand 1 (PD-L1)
Squamous cell carcinoma (SCC)
Therapy
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
03 02 2020
03 02 2020
Historique:
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
12
6
2021
Statut:
epublish
Résumé
Recent studies have evidenced the potential of combining anti-EGFR therapies with anti-PD-1/PD-L1 checkpoint therapies. Both anti-EGFR and anti-PD-1/PD-L1 have been separately tested in the treatment of cutaneous SCC (cSCC). Here, we review recent data on EGFR in the context of cancer progression, as a prognostic and as a therapeutic target in cSCC. Anti-EGFR/checkpoint immunotherapy and other combination therapy approaches are discussed. With the advent of immunotherapy, EGFR is still a valid cSCC target.
Identifiants
pubmed: 32016630
doi: 10.1007/s11864-019-0697-3
pii: 10.1007/s11864-019-0697-3
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Immune Checkpoint Proteins
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Références
Br J Dermatol. 2017 May;176(5):1279-1287
pubmed: 27510450
Br J Dermatol. 2011 Dec;165(6):1169-77
pubmed: 21777215
Cell. 2018 Oct 4;175(2):442-457.e23
pubmed: 30290143
Expert Opin Drug Saf. 2017 Apr;16(4):465-469
pubmed: 28271729
PLoS One. 2009;4(2):e4407
pubmed: 19197384
Clin Cancer Res. 2015 Mar 15;21(6):1447-56
pubmed: 25589618
J Dermatolog Treat. 2014 Oct;25(5):424-7
pubmed: 23167307
Australas J Dermatol. 2014 Feb;55(1):24-34
pubmed: 23425099
PLoS One. 2011;6(12):e29159
pubmed: 22195012
Prog Mol Subcell Biol. 2018;57:235-272
pubmed: 30097778
Curr Probl Dermatol. 2015;46:20-7
pubmed: 25561202
Exp Cell Res. 2009 Feb 15;315(4):683-96
pubmed: 19278030
Br J Cancer. 2007 Feb 12;96(3):408-16
pubmed: 17224925
Science. 2017 May 12;356(6338):617-624
pubmed: 28495747
J Invest Dermatol. 2010 Mar;130(3):901-3
pubmed: 19812598
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Open Access Maced J Med Sci. 2017 Dec 31;6(1):152-155
pubmed: 29484016
Hum Antibodies. 2010;19(4):89-99
pubmed: 21178280
Ann Oncol. 2014 Oct;25(10):2047-2052
pubmed: 25091317
Mol Cell Oncol. 2015 Jun 01;2(4):e1004969
pubmed: 27308503
Cancer. 1990 Oct 15;66(8):1692-6
pubmed: 1698529
J Immunother. 2017 Jan;40(1):36-38
pubmed: 27684455
Chin Med J (Engl). 2019 Feb;132(4):454-465
pubmed: 30707166
Am J Clin Oncol. 2000 Apr;23(2):181-4
pubmed: 10776981
Head Neck. 2011 Feb;33(2):286-8
pubmed: 19953623
J Invest Dermatol. 2019 Jan;139(1):213-223
pubmed: 30077724
Nature. 2015 Jan 22;517(7535):460-5
pubmed: 25517094
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Br J Dermatol. 2016 Dec;175(6):1382-1386
pubmed: 27059424
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2760-5
pubmed: 15701692
JAAD Case Rep. 2019 May 25;5(6):491-494
pubmed: 31193588
Cell Death Differ. 2019 Oct;26(10):2061-2073
pubmed: 30683916
J Skin Cancer. 2014;2014:284582
pubmed: 25136458
JAAD Case Rep. 2017 Sep 08;3(5):412-415
pubmed: 28932782
BJU Int. 2014 Jun;113(6):871-7
pubmed: 24053151
Dermatol Surg. 2010 Dec;36(12):2069-74
pubmed: 21044226
Front Med (Lausanne). 2019 Jul 10;6:160
pubmed: 31355203
Cell. 2000 Oct 13;103(2):211-25
pubmed: 11057895
J Clin Oncol. 2004 Jan 1;22(1):77-85
pubmed: 14701768
J Invest Dermatol. 1984 Nov;83(5):385-93
pubmed: 6092481
J Clin Oncol. 2007 May 20;25(15):1974-8
pubmed: 17513803
Eur J Cancer. 2018 Jul;97:7-15
pubmed: 29734047
J Am Acad Dermatol. 2020 Jan;82(1):139-148
pubmed: 31279037
EMBO J. 2013 Jul 31;32(15):2140-57
pubmed: 23799367
Epigenomics. 2016 Apr;8(4):501-18
pubmed: 27067026
Eur J Dermatol. 2018 Feb 1;28(1):78-81
pubmed: 29336323
Br J Dermatol. 2007 Jan;156(1):92-8
pubmed: 17199573
J Clin Oncol. 2000 Nov 1;18(21 Suppl):47S-53S
pubmed: 11060327
J Am Acad Dermatol. 2020 Feb;82(2):440-459
pubmed: 31163235
Clin Cancer Res. 2000 Jun;6(6):2166-74
pubmed: 10873065
Dermatol Surg. 2019 Jan;45(1):1-16
pubmed: 30045105
Clin Cancer Res. 2005 Jan 1;11(1):397-405
pubmed: 15671571
Traffic. 2014 Jun;15(6):648-64
pubmed: 24921075
Oncol Rep. 2009 Apr;21(4):1023-8
pubmed: 19288004
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Biomed Res Int. 2018 Apr 2;2018:9489163
pubmed: 29808169
Oncology. 2019;97(2):112-118
pubmed: 31112973
Cancer Lett. 2018 Apr 1;418:1-9
pubmed: 29309815
Cancer. 2016 Jan 15;122(2):249-57
pubmed: 26479420
Biophys J. 2006 Aug 1;91(3):857-65
pubmed: 16648169
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e257-e258
pubmed: 28557105
Sci Rep. 2017 Oct 4;7(1):12654
pubmed: 28978917
JAAD Case Rep. 2015 May 25;1(3):153-6
pubmed: 27051715
Arch Dermatol Res. 1989;281(2):83-8
pubmed: 2476080
JAMA Dermatol. 2017 Apr 01;153(4):291-298
pubmed: 28259104
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Cancer. 2018 May 15;124(10):2169-2173
pubmed: 29579331
Clin Cancer Res. 2012 Mar 1;18(5):1435-46
pubmed: 22261807
J Clin Med. 2018 Jan 10;7(1):
pubmed: 29320468
Cancer Sci. 2007 Aug;98(8):1275-80
pubmed: 17498200
Expert Opin Biol Ther. 2014 Feb;14(2):271-6
pubmed: 24387664
J Clin Oncol. 2011 Sep 1;29(25):3419-26
pubmed: 21810686
Oncol Lett. 2019 Jul;18(1):368-374
pubmed: 31289508
J Clin Oncol. 2020 Sep 10;38(26):3051-3061
pubmed: 32730186
Cold Spring Harb Perspect Biol. 2014 Mar 01;6(3):
pubmed: 24591517
J Clin Oncol. 2005 Mar 20;23(9):1803-10
pubmed: 15677699
Cancer Res. 2006 Apr 1;66(7):3603-10
pubmed: 16585185
J Dtsch Dermatol Ges. 2010 Oct;8(10):826-8
pubmed: 20731754
Onco Targets Ther. 2016 Feb 25;9:945-8
pubmed: 26955287
ESMO Open. 2016 Jan 18;1(1):e000003
pubmed: 27843579
J Am Acad Dermatol. 2017 Dec;77(6):1110-1113.e2
pubmed: 28964539
Curr Treat Options Oncol. 2019 Mar 14;20(4):30
pubmed: 30874952
Exp Hematol Oncol. 2018 Aug 28;7:20
pubmed: 30181930
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
JAMA Dermatol. 2016 Jan;152(1):106-8
pubmed: 26422398
Mol Clin Oncol. 2018 Jul;9(1):30-34
pubmed: 29977536
Br J Dermatol. 2015 Aug;173(2):527-34
pubmed: 25704233
J Med Imaging Radiat Oncol. 2019 Apr;63(2):257-263
pubmed: 30549229
Dermatology. 2014;229(2):97-101
pubmed: 24923455
J Dermatol. 2018 Jul;45(7):874-875
pubmed: 29971836
BMC Dermatol. 2014 Sep 30;14:15
pubmed: 25270710
Cell Cycle. 2014;13(5):681-2
pubmed: 24526125
Carcinogenesis. 2006 Feb;27(2):225-31
pubmed: 16123117
Chin Med Sci J. 1996 Jun;11(2):106-9
pubmed: 9387420
Head Neck. 2017 Mar;39(3):578-594
pubmed: 27882625